Is Clinitech Lab overvalued or undervalued?

As of 28 August 2025, Clinitech Lab's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 11.41, an EV to EBITDA ratio of 11.57, and a ROE of 10.99%. These metrics suggest that Clinitech Lab offers a compelling investment opportunity compared to its peers.
In the peer comparison, Clinitech Lab's PE ratio of 11.41 stands in stark contrast to Max Healthcare's exorbitant 93.61 and Apollo Hospitals' 70.56, both of which are categorized as very expensive. Additionally, Clinitech's PEG ratio is notably low at 0.00, further supporting the undervaluation narrative. While the stock has faced challenges with a year-to-date return of -36.6%, it has outperformed the Sensex over the past month, which saw a decline of 1.00%. This performance may indicate a potential recovery and growth trajectory for Clinitech Lab.